DocumentsDate added
ORIGINAL ARTICLE
Shrikant Gorakshnath Jadhav1,Vivek Viswanathan2,Alka Pravin Mukne2*
1Department of Pharmaceutical Analysis, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai, Maharashtra, India
2Department of Pharmacognosy and Phytochemistry, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai, Maharashtra, India
Address reprint requests to:
*Dr. Alka Pravin Mukne, Department of Pharmacognosy and Phytochemistry, Bombay College of Pharmacy, Kalina, Santacruz (East), Mumbai, Maharashtra, India
Article citation: Jadhav SG, Viswanathan V, Mukne AP. Validated HPTLC method for simultaneous quantification of isoniazid, rifampicin and glabridin. J Pharm
Biomed Sci 2016;06(07):453–459.Available at www.jpbms.info
ABSTRACT
A new, rapid and simple high performance thin layer chromatography technique for the simultaneous quantification of isoniazid, rifampicin and glabridin in combination is developed and validated. The method was developed by separating the constituents in pre-coated silica gel 60 F254 aluminium plate. The mobile phase for separation consisted of ethanol, ethyl acetate, dichloromethane and chloroform. The densitometric scanning of the plates post development was done at 254 nm which gave retention factors of 0.28 ± 0.005, 0.38 ± 0.007 and 0.75 ± 0.008 for isoniazid, rifampicin and glabridin respectively. The method was validated as per International Conference on Harmonization (ICH) for linearity, precision (repeatability and intermediate precision), accuracy, robustness, limit of detection and limit of quantification. The responses were found to be linear in the range of 200–400 ng/band for isoniazid and rifampicin, whereas the range was 400–800 ng/band for glabridin. Statistical analysis showed acceptable limits for precision, accuracy and robustness. Limit of detection and limit of quantification values for all the three drugs were estimated by signal to noise ratio method.
KEYWORDS glabridin, high performance thin layer chromatography, ICH, isoniazid, rifampicin, validation
REFERENCES:
1.Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ. 2008;336:484–487.
2.Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160–184.
3.Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Antimicrobial activity of licorice flavonoids against methicillin-resistant Staphylococcus aureus. Fitoterapia. 2002; 73:536–539.
4.Mitscher LA, Park YH, Clark D, Beal JL. Antimicrobial agents from higher plants. Antimicrobial isoflavanoids and related substances from Glycyrrhiza glabra L. var. Typica. J Nat Prod.1980;43:259–269.
5.Gupta VK, Fatima A, Faridi U, Negi AS, Shanker K, Kumar JK,et al. Antimicrobial potential of Glycyrrhiza glabra roots.J Ethnopharmacol. 2008;116:377–380.
6.Nair SS, Pharande RR, Bannalikar AS, Mukne AP. In vitro antimycobacterial activity of acetone extract of Glycyrrhiza glabra. J Pharm Pharmacogn Res. 2015;3:80–86.
7.Tim Cushnie TP, Lamb AJ. Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Ag.2011;38:99–107.
8.De La Iglesia AI, Morbidoni HR. Mechanisms of action of and resistance to rifampicin and isoniazid in Mycobacterium tuberculosis: new information on old friends. Revista Argentina de Microbiologia. 2006;38:97–109.
9.Korhalkar A, Deshpande M, Lele P, Modak M. Antimicrobial activity of Yashtimadhu (Glycyrrhiza glabra L.) – A Review. Int J Curr Microbiol App Sc. 2014;3:329–336.
10.Glass BD, Agatonovic-Kustrin S, Chen YJ, Wisch MH. Optimization of a stability-indicating hplc method for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a fixed-dose combination using artificial neural networks. J Chrom Sc. 2007;45:38–44.
11.Shah U, Jasani A. UV Spectrophotometric and RP-HPLC methods for simultaneous estimation of Isoniazid, Rifampicin and Piperine in pharmaceutical dosage form. Int J Pharm Pharmaceutical Sc. 2014;6:274–280.
12.Shah Y, Khanna S, Jindal KC, Dighe VS. Determination of rifampicin and isoniazid in pharmaceutical formulations by HPLC; Drug Dev. Ind Pharm. 1992;18:1589–1596.
13.Ali J, Ali N, Sultana Y, Baboota S, Faiyaz S. Development and validation of a stability-indicating HPTLC method for analysis of antitubercular drugs. Acta Chromatographia. 2007;18:168–179.
14.Sharma SC, Das S, Talwar SK. Spectrophotometric estimation of Rifampin-Isoniazid mixture in dosage form. J Assoc Off Anal Chem. 1987;70:679–681.
15.Arifa Begum SK, Basava Raju D, Rama Rao N. Simultaneous estimationof rifampicin and isoniazid in combined dosage form by a simple UV spectrophotometric method. Der Pharmacia Lett.2013;5:419–426.
16.Manna A, Ghosh I, Datta S, Ghosh PK, Ghosh LK, Gupta BK.Simultaneous estimation of isoniazid and rifampicin in combine dosage form. Ind J Pharm Sc. 2000;62:185–186.
17.Patil JS, Sarasija S, Sureshbabu AR, Rajesh MS. Development and validation of liquid chromatography-mass spectrometry method for the estimation of Rifampicin in plasma. Ind J Pharm Sc. 2011;73:558–563.
18.Srivastava A, Waterhouse D, Ardrey A, Ward SA. Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic–tandem mass spectrometric method. J Pharm Biomed Anal. 2012;70:523–528.
19.Shanker K, Fatima A, Negi AS, Gupta VK, Darokar MP, Gupta MM, et al. RP-HPLC Method for the Quantitation of Glabridin in Yashti-madhu (Glycyrrhiza glabra). Chromatographia. 2007;65:771–774.
20.Kamal YT, Singh M, Tamboli ET, Parveen R, Arif Zaidi SM, Ahmad S. Rapid RP-HPLC Method for the Quantification of glabridin in crude drug and in polyherbal formulation. J Chrom Sc. 2012;50:779–784.
21.Viswanathan V, Mukne AP. Development and validation of HPLC and HPTLC methods for estimation of gabridin in extracts of Glycyrrhiza glabra. J AOAC Int. 2016;99(2):374–379.
22.Singh M, Kamal YT, Tamboli ET, Parveen R, Ansari SH, Ahmad S. Glabridin, a Stable Flavonoid of Glycyrrhiza glabra: HPTLC analysis of the traditional formulation. J Planar Chrom. 2013;26:267–273.
23.Aoki F, Nakagawa K, Tanaka A, Matsuzaki K, Arai N, Mae T. Determination of glabridin in human plasma by solid-phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;828:70–74.
24.ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2 (R1), Nov 2005.
25.Ranjane PN, Gandhi SV, Kadukar SS, Bothara KG. HPTLC determination of cefuroxime axetil and ornidazole in combined tablet dosage form. J Chrom Sc. 2010;48:26–28.
26.Ansari MJ, Ahmad S, Kohli K, Ali J, Khar RK. Stability-indicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. J Pharm Biomed Anal. 2005;39:132–138.
27.Shewiyo DH, Kaale E, Risha PG, Dejaegher B, Smeyers-Verbeke J, Vander Hayden Y. HPTLC methods to assay active ingredients in pharmaceutical formulations: a review of the method development and validation steps. J Pharm Biomed Anal. 2012;66:11–23.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding:The work was supported by grant received from Department of Biotechnology, Government of India (Sanction order no. BT/PR5572/MED/29/534/2012 dated 13.06.2013).
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
ORIGINAL ARTICLE
Preeti B Agrawal*,Divyesh Goswami,Sajjan S Surana,Sujanani Shashi
Department of Pathology, Pacific Medical College and Hospital, Udaipur Rajasthan,India
Address reprint requests to:
*Dr Preeti B Agrawal, 174/A,P Road, Bhupalpura, Udaipur 313001,Rajasthan, India
Article citation: Agrawal PB, Goswami D, Surana SS, Shashi S. Pre-donation deferral of blood donors in tertiary care hospital attached to medical college in Southern Rajasthan. J Pharm Biomed Sci 2016;06(07):460–463. Available at www.jpbms.info
ABSTRACT
Purpose The primary objective of this study is to record and document the current rate and reason for donor deferral in our tertiary care hospital in Southern Rajasthan.
Method A retrospective study of donors was carried out from the donor records in the blood bank of a tertiary hospital during period of April 2014 to April 2016. Detailed information of the donor deferral was recorded from deferral register. We used statistical method to detect the rate and reason for donor deferral.
Result and Conclusion Every blood bank should analyze the reasons of deferral amongst blood donors and utilize this analysis for addressing the issue and ameliorating the cause of deferral if possible.
KEYWORDS blood donor, deferred donor, NACO, SBTC, Pre-donation deferral
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
ORIGINAL ARTICLE
YashPaul Dev Sharma,Preetinder Singh*,Raghav Yashbir,Kaur Manvir,Sharma Shivli,Wahi Ankur
Department of Periodontology and Oral Implantology, Swami Devi Dyal Hospital and Dental College, Barwala, Panchkula
Address reprint requests to:
*Preetinder Singh, Department of Periodontology and Oral Implantology,Swami Devi Dyal Hospital and Dental College, Barwala, Panchkula
Article citation: Sharma YD, Singh P, Yashbir R, Manvir K, Shivli S, Ankur W. Outcome of vitamin D supplementation on Implant osseointegration in patients suffering from chronic kidney disease: a prospective randomized study. J Pharm Biomed Sci 2016;06(07):445–452. Available at www.jpbms.info
ABSTRACT
Aim This study was aimed to investigate the effect of Vit D supplementation on implant osseointegration in CKD.
Settings and Design This was a prospective randomized study conducted on 20 patients with complaint of missing teeth and who had chronic kidney disease. After evaluation of the medical reports of the patients; medical consultancy was taken from the physician.
Materials and Methods Out of twenty patients ten were given vitamin D supplements (60,000 IU). Implants were placed under aseptic conditions. The following radiographic and clinical parameters were evaluated-1) Height of crestal bone. 2) Implant mobility. 3) Papilla fill index. 4) bleeding on probing.
Statistical Analysis Used The results were compiled and statistically analyzed using SPSS Version 19 Version. The Mann–Whitney U Test was used for the intergroup comparison and Wilcoxon Sign Rank Test for the intra-group comparison.
Results Statistically, significant results were seen in Group I, which were on vitamin D supplementation in relation to osseointegration when compared to group II. It demonstrated that weekly supplementation with 60,000 IU of cholecalciferol for 12 weeks is an effective way of correcting vitamin D status in patients with CKD stage 3 and 4 which also, helps in the formation of bone for osseointegration.
Conclusion Implants placed in patients with CKD on vitamin D supplementation were more successfully osseointegrated and functional, which was confirmed clinically and radiographically.
KEYWORDS dental implants; chronic kidney diseases; bone mineralization; osseointegration; parathyroid hormone (PTH)
REFERENCES:
1.Marakoglu I, Gursoy UK, Demirer S, Sezer H. Periodontal status of chronic renal failure patients receiving hemodialysis. Yonsei Med J. 2003;44(4):648–52.
2.Brasil. Ministério da Saúde. Painel de Indicadores do SUSNº7. Departamento de Monitoramento e Avaliação do SUS/ Secretaria de Gestão Estratégica e Participativa. Brasília, DF;2010.
3.Gonçalves EM, Karam LALL, Milfont TS, Araújo MD, Santana JML, Lima DLF. Prevalência de periodontite em pacientes submetidos a hemodiálise. J Bras Nefrol. 2007;29(3):115–9.
4.Pelletier S, Chapurlat R. Optimizing bone health in chronic kidney disease. Maturitas. 2010;65:325–33.
5.Ott SM. Bone disease in CKD. Curr Opin Nephrol Hypertens.2012;21:376–81.
6.Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Kidney Disease: Improving Global Outcomes(KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–53.
7.KDIGO. Clinical practice guideline for the diagnosis, evaluation,prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl.2009;S1–S130.
8.Lee MM, Chu EY, El-Abbadi MM, Foster BL, Tompkins KA, Giachelli CM, Somerman MJ. Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol.2010; 81:300–9.
9.Craig RG, Kotanko P, Kamer AR, Levin NW. Periodontal diseases–a modifiable source of systemic inflammation for the end-stage renal disease patient on haemodialysis therapy? Nephrol Dial Transplant. 2007; 22:312–5.
10.Stellingsma C, Vissink A, Meijer HJ, Kuiper C, Raghoebar GM.Implantology and the severely resorbed edentulous mandible. Crit Rev Oral Biol Med. 2004;15:240–8.
11.Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M,Kawagishi T, et al. Serum levels of 1,25-dihydroxyvitamin D,24,25-dihydroxyvitaminD, and 25- hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int. 1999;55:1019–27.
12.González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. American journal of nephrology.2004;24:503–10.
13.Rouached M, El Kadiri Boutchich S, Al Rifai AM, Garabedian M,Fournier A. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int.2008;74:389–90.
14.Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W,Someren JT, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008;14:10–17.
15.LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al.Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis.2005;45:1026–33.
16.Brinker MR, O’Connor DP, Monla YT, Earthman TP. Metabolic and endocrine abnormalities in patients with nonunions. J Orthop Trauma. 2007;21:557–70.
17.Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92:4–8.
18.Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.
19.Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73:1345–54.
20.Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.
21.Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, Donald J,et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21:1371–80.
22.Kelly J, Lin A, Wang CJ, Park S, Nishimura I. Vitamin D and bone physiology: demonstration of vitamin D deficiency in an implant osseointegration rat model. J Prosthodont. 2009;18:473–78.
23.Alvim-Pereira F, Montes CC, Thomé G, Olandoski M, Trevilatto PC. Analysis of association of clinical aspects and vitamin D receptor gene polymorphism with dental implant loss. Clin Oral Implants Res. 2008;19:786–95.
24.Jingushi S, Iwaki A, Higuchi O, Azuma Y, Ohta T, Shida JI, et al.Serum 1alpha,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology.139:1467–73.
25.Xu B, Zhang J, Brewer E, Tu Q, Yu L, Tang J, et al. Osterix enhances BMSC associated osseointegration of implants. J Dent Res. 2009;88:1003–07.
26.Mombelli A, van Oosten MAC, Schu¨r ch E, Lang NP. The microbiota associated with successful or failing osseointegrated titanium implants. Oral Microbiol Immunol. 1987;2:145–15.
27.Wasserman BH, Geiger AM, Turgeon LR. Relationship of occlusion and periodontal disease: VII. Mobility. J Periodontol. 1973;44:572–78.
28.Jemt T. Regeneration of papillae after single-implant treatment.Int J Periodontics Restorative Dent. 1997;17:327–33.
29.Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with endstage renal disease. Kidney Int. 2000;58:396–99.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
ZK Mohammed1,D Templeton2,Hajja Gana Hamza1,A Gidado1,IM Hussaini3
1 Department of Biochemistry, University of Maiduguri Nigeria
2 Department of Pathology, University of Virginia, Charlottesville, VA, USA
3 Faculty of Pharmacy, University of Maiduguri, Nigeria
Address reprint requests to:
Dr. Hajja Gana Hamza,
Department of Biochemistry, Faculty of Science,University of Maiduguri, Nigeria
Article citation: Mohammed ZK, Templeton D, Hamza HG, Gidado A, Hussaini IM. Detarium microcarpum stem bark extracts induce apoptosis in human breast adenocarcinoma MDA MB 231 cells via cJNK activation and mitochondrial cytochrome C release. J Pharm Biomed Sci 2016;06(07):439–444. Available at www.jpbms.info
ABSTRACT
Detarium microcarpum stem bark extract (DMSE) is one of the medicinal herbs used by the traditional medical practitioners in North East Nigeria to treat or manage various ailments such as wounds, inflammation and some form of malignancy. This study is an attempt to assess the anti-tumor activity of DMSE on human breast adenocarcinoma MDA MB 231 cells and the underlying mechanism involved in the anti-cancer activity. The survival rate of MDA MB 231 cells was reduced in a dose-dependent manner as assessed by MTT assay. Mitogen-activated protein kinase (cJunK) was phosphorylated shortly 1 h after treatment. The translocation of mitochondrial cytochrome C to the cytosol was observed after 3 h post-treatment. In conclusion, these results suggest that DMSE possibly causes mitochondrial damage leading to cytochrome release in cytosol and the activation of c-JUN kinase resulting in apoptosis of human breast adenocarcinoma MDA MB 231 cells.
KEYWORDS Deterium microcarpum, stem bark extract, apoptosis.
REFERENCES
1.Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–90.
2.Ebi GC, Afieroho OE. Phytochemical analysis and antimicrobial studies on D. microcarpum (Guill and Sperr) Seeds. Afr J Biotech.2011;10:10457–62.
3.Gogvadze V, Orrenius S, Zhivotovsky B. Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta. 2006;1757:639–47.
4.Goldstein JC, Muñoz-Pinedo C, Ricci JE, Adams SR, Kelekar A, Schuler M, et al. Cytochrome c is released in a single step during apotosis. Cell Death Differ. 2005;12:453–62.
5.Hamza HG, Saleh AI, Mohammed ZK, Ngadda HA. Effect of aqueous extract of Detarium microcarpum (Guill & Sperr) on mycotoxin-induced tissue damage in albino rats. J Pharm Biomed Sci. 2014;04:92–99.
6.Hamza-Idris H, Oyeanusi SA. In vitro evaluation of stembark extract of Detarium microcarpum (Guill & Sperr) for antimicrobial activity. Nig J Exp Appl Biol. 2012;13(1):55–59.
7.Li CJ, Wang C, Pardee AB. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res. 1995;55:3712–15.
8.Mohammed ZK, Daja M, Hamza HG, Gidado A, Hussaini IM. Ethnomedicinal survey of folkloric plants used in managing breast cancers by the traditional medical practitioners of North-East Nigeria. J Med Appl Bioscience. 2014;6(1):29–43.
9.Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.J Immunol Methods. 1983;65: 55–63.
10.Musílková J, Kovár J. Additive stimulatory effect of extracellular calcium and potassium on non-transferrin ferric iron uptake by HeLa and K562 cells. Biochim Biophys Acta. 2001;1514:117–26.
11.Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell.2003;112:481–90.
12.Olugbuyiro JAO, Moody JO, Hamann MT. Inhibitory activity of Detarium microcarpum extract against hepatitis C virus Afr J Biomed Res. 2009;12(2):146–51.
13.Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, et al. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53 independent response. Cancer Res. 1995;55:3706–11.
14.Sumitra C, Krunal N. In vitro and in vivo methods for anticancer activity evaluation and some indian medicinal plants possessing anticancer properties: an overview. J Pharmacog Phytochem.2013;2;140–52.
15.Li YZ, Li CJ, Pinto AV, Pardee AB. Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by 8-lapachone in human carcinoma cells. Mol Med. 1999;232–39.
16.Xing C, Yuping D, Jing N, Xinxin Z, Xiaodong Q, Yuxin W,et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLOS One.2013;8;e63697
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: TETFund Nigeria.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
CASE REPORT
Amit Mhapuskar, Rakhee Modak*, Darshan Hiremutt, Santosh Jadhav
Department of Oral Medicine and Radiology, Bharati Vidyapeeth Deemed University Dental College and Hospital, Pune, India
Address reprint requests to:
*Rakhee Modak,
Department of Oral Medicine and Radiology, Bharati Vidyapeeth Deemed University Dental College and Hospital, Pune, India
Article citation: Mhapuskar A, Modak R, Hiremutt D, Jadhav S. Aneurysmal bone cyst of mandible: a case report and review of literature. J Pharm Biomed Sci 2016;06(07):433–438.
Available at www.jpbms.info
ABSTRACT
An aneurysmal bone cyst is a rare benign expanding osteolytic lesion of bone characterized by replacement with fibro-osseous tissue containing blood filled sinusoidal or cavernous spaces of variable size. Aneurysmal bone cyst are infrequent in craniofacial skeleton and among all cystic lesions that can be found in maxilla and mandible it is rare, most commonly found in long bones and vertebral column. The development of aneurysmal bone cyst is related to history of trauma and subperiosteal hematoma formation. In this article we present a case of 40-year-old female patient with an aneurysmal bone cyst involving right angle and ramus of mandible. Computed Tomography of mandible revealed a well-defined expansile lesion in the region of the angle and ramus of right hemi mandible with thinning of bony cortex and diagnosis was confirmed by histopathological examination. In our patient, en block (The resection of large bulky tumor virtually without dissection) resection allowed complete removal of the lesion and reconstruction plate was placed for rehabilitation. We have focused on differential diagnosis of lesions that are found at this location and histopathological examination remains the Gold Standard in confirmatory diagnosis of such lesions.
KEYWORDS aneurysmal bone cyst, ameloblastoma, osteolytic bone neoplasm, hemi mandiblectomy.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.